

WORLDWIDE APPROVAL

TIVICAY 50mg TABLETS

Albania Ghana Niger Argentina Guatemala Nigeria Armenia Guinea Oman Aruba Guyana **Pakistan** Australia Haiti Panama Azerbaijan Honduras Peru

Bahrain Hong Kong Philippines Bangladesh Israel Qatar

Belarus Jamaica Russian Federation

Bosnia and Herzegovina Japan Saudi Arabia Botswana Jordan Senegal Brazil Kazakhstan Serbia

Burkina Faso Kenya Sierra Leone Cameroon Kuwait Singapore Canada South Africa Kyrgyzstan Lebanon South Korea Central Africa Republic Chad Liberia Suriname Chile Switzerland Macau China Macedonia Taiwan

Colombia Malawi Tanzania
Congo Malaysia Thailand
Costa Rica Mali Togo

Cote D'Ivoire Mauritius Trinidad and Tobago

Curacao Mexico Turkey
Democratic Republic of Congo Moldova Uganda
Dominican Republic Mongolia Ukraine

Ecuador Montenegro United Arab Emirates
Egypt Morocco United States of America

El Salvador Mozambique Uruguay
Ethiopia Myanmar Uzbekistan
European Union Namibia Zambia
Gabon New Zealand Zimbabwe

Georgia Nicaragua

This document was prepared on 14 March 2019 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.

^{✓ &}quot;Approval" means: Marketing Authorisation has been granted by a country <u>or</u> there is no formal regulatory process in place, in the relevant country.

[✓] Granted Marketing Authorisations may include limitations on the use of the product.